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Background: We sought to investigate the prevalence and variables associated with Early 48 
Oncologic Failure (EOF). 49 
Methods: Retrospective review of the IRCC database of patients who underwent robot-assisted 50 
radical cystectomy (RARC) since 2003. The final cohort comprised 1894 patients (23 institutions 51 
from 11 countries). EOF was defined as any disease relapse within 3 months of RARC. All 52 
institutions were surveyed for the pneumoperitoneum pressure used, breach of oncological 53 
surgical principles and technique of specimen and lymph node removal. Multivariate model was 54 
fit to evaluate predictors of EOF. The Kaplan Meier method was used to depict disease-specific 55 
(DSS) and overall survival (OS) and Cox proportional regression analysis to evaluate predictors 56 
of DSS and OS.  57 
Results: 305 patients (22%) experienced disease relapse, 220 (16%) distant, 154 (11%) local 58 
recurrence, 17 (1%) peritoneal carcinomatosis and 5 (0.4%) port-site recurrences. Seventy-one 59 
patients (5%) from 10 institutions developed EOF, and the incidence of EOF decreased from 60 
10% in 2006 to 6% in 2015.  On multivariate analysis, presence of any complication (OR 2.87; 61 
95% CI 1.38-5.96; p=0.004), ≥pT3 disease (OR 3.73, 95% CI 2.00-6.97, p<0.001), and nodal 62 
involvement (OR 2.14, 95% CI 1.21-3.80, p=0.008) were significant predictors of EOF. Patients 63 
with EOF demonstrated worse DSS and OS (23% and 13%) at 1 and 3 years when compared to 64 
patients who experienced later or no recurrences (log rank p<0.001)  65 
Conclusion: The incidence of EOF following RARC has decreased with time. Disease-related 66 
rather than technical-related factors play a major role in occurrence of EOF after RARC. 67 
 68 
 69 
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Introduction 70 
Radical cystectomy (RC) with pelvic lymph node dissection (pLND) represents the gold 71 
standard for management of non-metastatic muscle invasive bladder cancer (MIBC) and 72 
refractory non-muscle invasive disease. More interest has been spurred in robot-assisted radical 73 
cystectomy (RARC) aiming to improve perioperative outcomes, including blood loss, transfusion 74 
rates, hospital stay and recovery without compromising oncological efficacy 1,2. Consequently, 75 
the past decade has witnessed a paramount shift in the utilization of RARC (from <1% in 2004 to 76 
13% in 2010) 2. Nevertheless, much of the criticism to RARC has been attributed to lack of long 77 
term oncologic outcomes and patient selection bias. There have also been concerns regarding 78 
adherence to key oncologic tenets and induction of local pelvic, peritoneal and port-site 79 
recurrences during minimally invasive approaches to RC 3. 80 
Despite aggressive management, more than half of patients with MIBC will relapse 81 
(locally or systemically), usually within the first 2 years  after surgery with deleterious impact on 82 
survival 4. Extent of the disease at the time of surgery or the breach of oncologic surgical may 83 
contribute to disease relapse. Known predictors of disease relapse include perioperative 84 
chemotherapy, extent of pLND, pathological T stage, lymph node status, and positive soft tissue 85 
surgical margins at cystectomy 5.  86 
In this study we queried the multi-national, prospectively maintained, quality assurance 87 
database—the International Robotic Cystectomy Consortium (IRCC) to investigate the 88 
prevalence of early oncologic failure (EOF) after RARC. EOF was defined as any disease 89 
relapse within the first 3 months following surgery, among patients who underwent RARC over 90 
more than a decade, and further to investigate the possible factors contributing to EOF. To our 91 
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knowledge, this is the first paper to address possible early recurrences related to technical faults 92 
after RARC. 93 
Methods 94 
A retrospective review of 2460 patients from 29 institutions included in the IRCC 95 
database (I-97906) was performed. Institutions (n=566) that failed to provide updated data were 96 
excluded from the study. The final cohort comprised 1894 patients from 23 institutions across 11 97 
countries who were treated with RARC since 2003 (Figure 1). Data were reviewed for age, 98 
gender, body mass index [BMI], and American Society of Anesthesiologists [ASA] score, 99 
preoperative characteristics (neoadjuvant chemotherapy, prior abdominal surgery, and clinical 100 
staging), operative variables (type and technique of diversion, operative time, estimated blood 101 
loss, and blood transfusion), perioperative outcomes (complications, readmissions, hospital and 102 
intensive care unit stay), and pathologic outcomes (staging, lymph node yield and soft tissue 103 
surgical margins). Technique of RARC and urinary diversion, and follow up differed among 104 
institutions.  105 
Disease relapses were defined in terms of recurrence type (local, distant, port-site or 106 
peritoneal carcinomatosis), anatomical site, and timing since cystectomy (EOF—defined as any 107 
disease relapse within 90 days following RARC; versus later; or no recurrences). Ninety days 108 
was chosen as a cut off for EOF so that these recurrences are most likely related to the surgical 109 
technique rather than the disease severity. All patients had at least 3 months of follow up. 110 
Institutions having patients with EOF were surveyed for their use of pneumoperitoneum 111 
pressure, breach of oncological principles during RARC including spillage of urine during the 112 
procedure, and the technique of specimen and lymph node removal.  113 
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Descriptive statistics were used to summarize the data. Univariable associations were 114 
statistically assessed using Pearson Chi-square or Fisher’s Exact test. Univariate and multivariate 115 
(stepwise variable selection) logistic regression models were fit to evaluate preoperative, 116 
operative, and postoperative predictors of EOF following RARC. The Kaplan Meier method was 117 
used to depict disease-specific (DSS) and overall survival (OS) for patients with EOF versus 118 
those who did not exhibit EOF. All tests were two-sided, with statistical significance defined as 119 
p<0.05. All statistical analyses were performed using SAS software (version 9.4, SAS Institute 120 
Inc., Cary, NC). 121 
Results 122 
Of the 1894 patients included in the study, 30 patients died because of non-cancer related 123 
causes and 484 had incomplete recurrence data. A total of 1380 patients had complete data were 124 
included in the final analysis (Figure 1). After a mean follow up of 24 months, 305 patients 125 
(22%) experienced disease relapse; 220 (16%) developed distant, 154 (11%) local recurrence, 17 126 
(1%) peritoneal carcinomatosis and 5 (0.4%) port-site recurrences. Seventy-one patients (5%) 127 
from 10 institutions developed EOF, and the incidence of EOF decreased from 10% in 2006 to 128 
6% in 2015 (Figure 2). Compared with patients who developed later or no recurrences, patients 129 
who experienced EOF significantly experienced higher estimated blood loss, received blood 130 
transfusion and adjuvant chemotherapy more frequently, and demonstrated higher complication 131 
rate. EOF patients when compared to those who developed recurrences > 3 months and those 132 
without any recurrences, had higher prevalence of pT3, (75% versus 68% and 31%, respectively, 133 
p<0.001), and positive nodal disease (42% versus 36% and 15%, respectively, p<0.0001). They 134 
had higher positive soft tissue surgical margins compared to patients who did not have any 135 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
recurrences (13% versus 6%, p<0.001) (Table 1). Eight patients experienced EOF despite having 136 
organ confined disease (<pT3 and N0). Of these, 3 had breech of oncologic surgical principles.  137 
Overall, the pelvis was the commonest site for local recurrence (51%). The lung was the 138 
most common site for distant recurrence (24%) followed by bone metastasis (21%) and 139 
extrapelvic lymph node (20%). When compared to those who developed later recurrences, 140 
patients with EOF experienced more pelvic recurrences (37% versus 22%, p=0.02), extrapelvic 141 
lymph node metastasis (23% versus 12%, p=0.03), and bone metastasis (24% versus 12%, 142 
p=0.03) (Table 2).  143 
We surveyed the 10 institutions that had patients with EOF. Four institutions operated at 144 
higher pneumoperitoneum pressures (≥14 mmHg), while the remaining operated at ≤12 mmHg. 145 
Of patients who developed EOF, 4 patients from 2 institutions had possible disseminated disease 146 
on preoperative metastatic work up. Breaching of oncologic principles occurred in 6 patients 147 
(Table 3). 148 
On multivariate analysis, presence of any complication (Odds ratio [OR] 2.87; 95% 149 
confidence interval [CI] 1.38-5.96; p=0.004), extravesical disease (OR 3.73, 95% CI 2.00-6.97, 150 
p<0.001), and nodal involvement (OR 2.14, 95% CI 1.21-3.80, p=0.008) were significant 151 
predictors of EOF (Table 4). Patients with EOF demonstrated worse DSS (32% and 26%) and 152 
OS (23% and 13%) at 1 and 3 years when compared to patients who experienced later 153 
recurrences (DSS 81% and 39%; OS 74% and 25%) and no recurrences (DSS 99% and 96%; OS 154 
93% and 82%) (log rank p<0.001) (Figures 3 and 4). On Cox proportional hazards analysis, 155 
patients with pT≥3, nodal involvement, and presence of positive soft tissue surgical margins 156 
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exhibited worse DSS and OS. Patients who received neobladders demonstrated better OS (HR 157 
0.49, 95% CI 0.31-0.75, p=0.001) (Table 5).  158 
Discussion 159 
Despite aggressive management, disease relapse after RC will occur in half of the 160 
patients which significantly reduces survival. The pathogenesis of recurrence following RC is yet 161 
to be determined but it is probably multifactorial. Tumor aggressiveness, occult metastatic 162 
disease at the time of surgery, inhibited host immune response, laparoscopy-related factors (gas 163 
insufflation and desufflation), or breaching of oncologic surgical principles (vigorous surgical 164 
manipulation, specimen morcellation, entry into the bladder, and retrieval method) have been 165 
investigated 6-8. The contribution of carbon dioxide (CO2) pneumoperitoneum deployed in 166 
minimally invasive surgery remains unknown. Prior animal studies suggested that CO2 167 
pneumoperitoneum may inhibit peritoneal immune response against malignant urothelial cells 168 
and may be contributing to recurrences within the pelvis and at port sites 9. 169 
We identified and characterized patients who developed EOF after RARC. Five percent 170 
of our patients experienced EOF, of these 63 (89%) had advanced disease (≥pT3 +/- positive 171 
nodal disease), and oncologic principles were breached in 6 (8%), 3 of them had organ confined 172 
disease (<pT3/N0). For any RC performed (open and RARC), tumor stage, nodal involvement, 173 
lympho-vascular invasion and positive soft tissue surgical margins are the most powerful 174 
predictors of tumor recurrence 1,10. On multivariable analysis, patients with extravesical or nodal 175 
disease were at least twice as likely to develop EOF. During RC, tumor spillage may occur with 176 
extravesical disease, extensive nodal involvement, or due to technical error, which may risk 177 
seeding the peritoneal cavity with urothelial cell carcinoma (UCC). The potential seeding of 178 
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tumor cells as a source for the local recurrences is a concern during open and minimally invasive 179 
RC. While much attention has been given to reporting negative soft tissue surgical margins, 180 
measures to prevent urine leakage from the urethra or the ureters should be routine 11. A survey 181 
of 162 members of the Society of Urologic Oncology revealed that 71% use urethral 182 
catheterization, 44% clamp the urethra and 22% ligate or clip the urethra at RC to prevent urine 183 
spillage 12. The Roswell Park Cancer Institute group initiated a novel approach to objectively 184 
evaluate the presence of cancer cells and their gene-related products in the pelvis and 185 
pneumoperitoneum during RARC 13. UCC, presumably from tumor spillage during transurethral 186 
resection of bladder tumor (TURBT) or after open RC, or from circulating tumor cells, has been 187 
reported in abdominal wounds, suprapubic tube sites, in the pelvic cavity (resection bed), and on 188 
the psoas muscle 14-16. The use of intravesical instillation of chemotherapy after TURBT to 189 
prevent tumor seeding and decrease recurrence inspired some surgeons to use sterile water to 190 
induce hypotonic lysis of any remaining UCCs despite the unproven efficacy 17. This raises 191 
questions about the possible role of intraperitoneal chemotherapy similar to ovarian, gastric and 192 
colorectal malignancies 18,19. The use of prophylactic radiation or systemic chemotherapy in the 193 
setting of UCC spillage remains unclear with significant potential morbidity.  194 
It is worth mentioning that the incidence of EOF decreased with time (from 10% in 2006 195 
to 6% in 2015). If these recurrences are surgery-related, then this trend might be explained by the 196 
evolution of the technique of RARC, the learning curve, experience with the procedure, and 197 
comfort with the robot-assisted platform for surgery 20. Blood transfusion and poor renal function 198 
have been proposed to induce recurrences by affecting the immunity and DNA repair 21. 199 
Although patients who had any recurrence received blood transfusion more frequently, it did not 200 
reach statistical significance on multivariable analysis. Patients who received neobladders 201 
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exhibited better OS (HR 0.49). Possible explanation is patient selection, where patients who 202 
received neobladders are generally of better health and less comorbidities, and further explains 203 
why the type of diversion affected OS and not CSS. Patients who developed postoperative 204 
complications were approximately 3 times more likely to develop EOF. Complications 205 
(especially intraoperatively or early in the postoperative period) may be a result of suboptimal 206 
surgical performance and therefore impact cancer control and patient survival 22.  207 
To our knowledge, no study reported early oncologic failures, but time to oncologic 208 
failure has been shown to be a significant predictor of OS after open RC 4. Nine percent early 209 
unexpected relapses were observed in a cohort of patients with favorable pathology (pT2 N0 Ro 210 
or less) in the European Association of Urology Section of Uro-Technology (ESUT) cohort 23. 211 
Similar to our study, they found that disease stage rather than technical factors is the main reason 212 
for early failures. However, they defined early failure as disease recurrence within 24 months 213 
after surgery. Since most recurrences after RC develop within the first 2 years after surgery, a 214 
period of 24 months will make it harder to differentiate recurrences that occur due to tumor 215 
biology from those that may have occurred due to breech of oncologic surgical principles. For 216 
this reason, we defined EOF as any disease relapse that occurred within the first 3 months after 217 
RARC. Patients with EOF demonstrated worse DSS and OS when compared to patients who 218 
experienced later recurrences and no recurrences (log rank p<0.0001). Early failures may be a 219 
result of unrecognized metastatic disease before surgery, or occurs as a result of tumor spillage 220 
during the procedure. Current imaging techniques lack adequate sensitivity and specificity, 221 
especially in low-volume metastatic disease. Moreover, it has been shown that in patients with 222 
presumably organ confined disease; micrometastatic disease was detected using RT-PCR studies 223 
in up to one third of patients with histologically negative lymph nodes 24,25. Similarly, patients 224 
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with colorectal, ovarian and urothelial cancers with local relapse, port site seeding and early 225 
metastasis after minimally invasive surgery have been previously reported 20,26. It remains 226 
difficult to determine whether such recurrences occurred due to the primary tumor stage or as a 227 
result of the surgical procedure itself. The use of quality scoring can objectively assess and 228 
quantify surgical performance and assess the surgical factors that may be contribute to EOF 22. 229 
Interestingly, pneumoperitoneum pressure was not associated with EOF. Prior reports 230 
suggested that high and/or pulsatile pneumoperitoneum, especially in lengthy procedures, may 231 
enhance migration tumor cells from the venous plexus of the bladder (whose pedicles are 232 
squeezed throughout the procedure) and contribute to early tumor recurrence 6,27,28. Identifying 233 
patients who are at higher risk for EOF will provide valuable information for technique 234 
modification, preventive measures, patient counselling, risk stratification and prognostication. 235 
Despite the emerging role of RARC as a viable alternative to the open traditional 236 
approach, criticisms regarding the RARC literature include lack of long term survival data, 237 
inherent patient selection bias, in addition to longer operative times and associated cost. In our 238 
cohort, EOF patients experienced more extrapelvic lymph node metastasis when compared to 239 
later recurrences (23% versus 12%, p=0.03). Nguyen et al suggested that recurrence patterns may 240 
differ between open and RARC. They reported higher incidence of extrapelvic lymph node 241 
metastasis and peritoneal carcinomatosis with RARC 29. Less thorough lymph node dissection 242 
with RARC and possible peritoneal dissemination of malignant urothelial cells with 243 
pneumoperitoneum have been considered responsible for these findings 30. However, the lymph 244 
node yield in the same study was similar for either approach and the differences reported were 245 
not statistically significant. Additionally, the approach to performing cystectomy was not a 246 
significant predictor on multivariable analysis 30. In our cohort, peritoneal carcinomatosis 247 
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occurred in less than 1% of all patients, and represented 4% of all recurrences. The difference in 248 
peritoneal carcinomatosis rates may be in part attributed to variation in defining carcinomatosis, 249 
sample size, follow up duration and perhaps surgical technique.  250 
Despite the uniqueness of this study, the retrospective study design and the multi-251 
institutional and multi-national databases have their recognized limitations. Recall bias may be 252 
an issue when looking at the surgical factors affecting EOF. Also, heterogeneity in surgical 253 
techniques, pathological examination and institutional follow-up protocols may lead to variation 254 
in reporting outcomes. However, the IRCC represents the largest multinational database for 255 
RARC that captures and reflects real-world practices. The lack of similar open reports examining 256 
early failures in open RC literature limits any comparison with RARC. 257 
Conclusion 258 
The incidence of EOF following RARC is low and has decreased with time. Disease-259 
related rather than technical or laparoscopy-related factors play a major role in occurrence of 260 
EOF after RARC. 261 
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Table 1. Demographics, clinical characteristics and perioperative outcomes of patients who 
experienced EOF after RARC versus those who did not. 
Preoperative parameters EOF Later Recurrence No Recurrence p-value 
N of patients (%) 71 234 1075 - 
Age at cystectomy, mean (SD) (yr) 64 (13) 68 (10) 67 (10) 0.02 
Gender, Males n (%) 47 (66) 176 (75) 788 (74)  0.31  
Body Mass Index, mean (SD) (kg/m2) 26.7 (5.1) 27.2 (5.5) 27.7 (5.2) 0.20 
ASA score, mean (SD) 2 (0.70) 2 (0.65) 2 (0.67) 0.38 
Prior abdominal/pelvic surgery, n (%) 26 (52) 69 (46) 299 (48) 0.76 
Neo-adjuvant chemotherapy, n (%) 16 (25) 45 (20) 207 (21) 0.68 
Perioperative outcomes 
Type of diversion, Ileal conduit, n (%) 55 (86) 188 (87) 810 (81) 0.08 
Technique of diversion, Intracorporeal, n (%) 39 (75) 127 (72) 642 (82) 0.007 
Operative time, median (min) (IQR) 392 (328-474) 373 (316- 454) 374 (311- 451) 0.65 
Estimated blood loss, mean (ml) 541 (690) 498 (417) 383 (411) <0 .001 
Blood Transfusion, n (%) 7 (10) 25 (11) 67 (6) 0.038 
Adjuvant chemotherapy, n (%) 29 (45%) 94 (44%) 72 (8%) < 0.001 
Hospital stay, mean (SD) (d) 12 (10) 12 (9) 12 (12) 0.32 
Intensive Care Unit stay, mean (SD) (d) 1 (3) 1 (3) 1 (2) 0.70 
Postoperative complications, n (%) 
• Any complication 53 (75) 147 (63) 615 (57) 0.007 
• Clavien 3-5 14 (20) 27 (12) 131 (12) 0.159 
• 30-d complications 29 (41) 76 (33) 294 (27) 0.001 
 • 30-90 d complications 7 (10) 17 (7) 60 (6) 
• > 90-d complications 4 (6) 28 (12) 75 (7) 
Follow up, median (months) (IQR) 4 (3-11) 15 (9-27) 19 (8-32) < 0.001 
Time to recurrence, median (months) (IQR) 2 (1-3) 8 (5-17) -  
Pathological outcomes 
Pathologic T stage, ≥pT3, n (%) 51 (75) 148 (68) 317 (31) < 0.001 
Lymph node yield, mean  16 (10) 18 (12) 18 (11) 0.402 
N positive, n (%) 30 (42) 84 (36) 159 (15) < 0.001 
Positive surgical margins, n (%) 9 (13) 31 (13) 65 (6) < 0.001 
EOF, early oncologic failure; SD, standard deviation; Kg/m2, Kilogram per square meters; Ml, milliliter 
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Table 2. Sites of disease relapse as a proportion of all relapses (distant+local) 
Local recurrence 
 
 EOF Later 
recurrences 
p-value 
 
Pelvis 26 (37) 52 (22) 0.02 
Vagina 1 (1) 3 (1) 1.00 
Rectum 4 (6) 9 (4) 0.51 
Perineum 4 (6) 8 (3) 0.49 
Urethra 0 6 (3) 0.34 
Penile 2 (3) 0 0.06 
Neobladder/Conduit 2 (3) 2 (1) 0.24 
Kidney 1 (1) 3 (1) 1.00 
Multiple Local  7 (10) 15 (6) 0.48 
Unidentified site 2 (3) 34 (15) NA 
Distant recurrence EOF Later 
recurrences 
p-value 
 
Nodal 16 (23) 27 (12) 0.03 
Lung 11 (15) 41 (18) 0.83 
Liver 10 (14) 15 (6) 0.07 
Bone 17 (24) 29 (12) 0.03 
Brain 3 (4) 2 (1) 0.09 
Abdominal wall 2 (3) 5 (2) 0.67 
Multiple distant 17 (24) 24 (10) 0.006 
Unidentified site 7 (10) 88 (38) NA 
Peritoneal carcinomatosis 6 (8) 11 (5) 0.25 
Port-site recurrence 3 (4) 2 (1) 0.09 
Local and distant recurrence 20 (28) 53 (23) 0.43 
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Table 3. Surveys collected from the lead surgeons of the institutions whose patients experienced 
EOF.  
Survey  n (%) 
Patients with EOF, n 71 
Institutions, n 10 
Suspicious preoperative metastatic work up, n (%) 3 (4)* 
Pneumoperitoneum pressure used (12 or less mmHg), n 
(%)                                                     
13 (18) 
Inadvertent Bladder Entry  1 (1) 
Urine spillage  2 (3) 
Tumor Spillage 2 (3) 
Ureters and urethra not clipped before extirpation  0 
Specimen (bladder/Lymph nodes) not retrieved in a bag 1 (1) 
*
 Two patients had possible nodal disease and 1 had possible lung 
metastasis on preoperative metastatic work up 
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Table 4. Univariate and multivariable regression modeling predictors for EOF (stepwise variable 
selection) 
 
Variables [Reference] 
Univariate Multivariate 
OR  95% CI p-value OR  95% CI p-value 
Preoperative parameters    
Age at cystectomy 0.97 (0.95, 0.99) 0.01 - - - 
Gender [Female] 0.69 (0.43, 1.14) 0.14 - - - 
Body Mass Index 0.97 (0.92, 1.02) 0.18 - - - 
ASA score 0.77 (0.52, 1.13) 0.18 - - - 
Neo-adjuvant chemotherapy  1.28 (0.72, 2.29) 0.41 - - - 
Operative    
Type of diversion [Ileal Conduit] 0.73 (0.36, 1.50) 0.39 - - - 
Technique of diversion [Extracorporeal] 0.73 (0.38, 1.40) 0.35 - - - 
Operative time  1.08 (0.94, 1.23) 0.28 - - - 
Estimated blood loss  1.05 (1.00, 1.09) 0.03 - - - 
Blood Transfusion  1.45 (0.64, 3.25) 0.37 - - - 
Adjuvant therapy  4.45 (2.66, 7.47) < 0.001 - - - 
Intensive care unit stay 1.02 (0.90, 1.16) 0.76 - - - 
Hospital stay 1.00 (0.98, 1.02) 0.91 - - - 
Any complication  2.11 (1.22, 3.65) 0.006 2.87 (1.38, 5.96) 0.004 
Clavien ≥ 3 complications  1.79 (0.97, 3.29) 0.06 - - - 
Pneumoperitoneum pressure [12mmHg] 1.47 (0.79, 2.76) 0.22 - - - 
Breaching of oncologic principles [No] 1.52 (0.86, 2.71) 0.15 -  - - 
Pathologic    
≥pT3 stage  4.95 (2.82, 8.67) < 0.001 3.73 (2.00, 6.97) < 0.001 
pN1 3.21 (1.96, 5.25) < 0.001 2.14 (1.21, 3.80) 0.008 
Lymph Node Yield 0.99 (0.96, 1.01) 0.22 - - - 
Positive surgical margins [No] 1.83 (0.88, 3.80) 0.10 - - - 
RARC, robotic-assisted laparoscopic radical cystectomy; SD, standard deviation; NA, odds ratio calculation impossible 
due to zero cell count(s) 
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Table 5. Cox proportional hazards modelling predictors of DSS and OS 
Overall survival 
Parameter HR 95% CI p-value 
≥pT3 3.302 2.56-4.25 <.0001 
pN1 1.796 1.40-2.30 <.0001 
Positive margins 1.578 1.13-2.21 0.0076 
Neobladders 0.484 0.31-0.75 0.0012 
Disease-specific survival 
Parameter HR 95% CI p-value 
≥pT3 4.94 3.30-7.40 <0.0001 
pN1 2.26 1.58-3.22 <0.0001 
Positive margins 1.64 1.03-2.63 0.04 
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Figure 1. Study cohort 
 
Figure 2. EOF cases as they occurred with time (Linear Regression Test p = 0.15) 
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Figure 3. Kaplan Meier curves for OS (log rank p <0.001) 
 
EOF Patients 
Months 0-6 6-12 12-18 18-24 24-30 30-36 
Patients At Risk 71 30 12 8 6 6 
Patient Deaths 36 14 3 2 0 0 
Survival % 46.6 22.8 16.7 12.5 12.5 12.5 
 
Later Recurrence 
Months 0-6 6-12 12-18 18-24 24-30 30-36 
Patients At Risk 234 211 152 100 68 49 
Patient Deaths 14 42  40 24 14 10 
Survival % 93.9 74.4 54.1 40.6 31.8 24.8 
 
No Recurrence 
Months 0-6 6-12 12-18 18-24 24-30 30-36 
Patients At Risk 1075 894 698 552 434 312 
Patient Deaths 28 32 23 15 10 12 
Survival %  97.2 93.4 90.0 87.3 85.0 81.5 
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Figure 4. Kaplan Meier curves for DSS (log rank p <0.001) 
 
EOF Patients 
Months 0-6 6-12 12-18 18-24 24-30 30-36 
Patients At Risk 71 30 12 8 6 6 
Patient Deaths 31 9 2 0 0 0 
Survival % 51.4 32.2 25.8 25.8 25.8 25.8 
 
Later Recurrence 
Months 0-6 6-12 12-18 18-24 24-30 30-36 
Patients At Risk 234 211 152 100 68 49 
Patient Deaths 9 31 32 16 9 5 
Survival % 96.0 80.8 62.6 51.8 44.3 39.4 
 
No Recurrence 
Months 0-6 6-12 12-18 18-24 24-30 30-36 
Patients At Risk 1075 894 698 552 434 312 
Patient Deaths 4 7 4 3 20 3 
Survival % 99.6 98.7 98.1 97.5 96.9 95.9 
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List of Abbreviations 
• Robot-assisted radical cystectomy (RARC) 
• Early Oncologic Failure (EOF). 
• Radical cystectomy (RC) 
• Pelvic lymph node dissection (pLND) 
• Muscle invasive bladder cancer (MIBC) 
• International Robotic Cystectomy Consortium (IRCC) 
• Body mass index (BMI) 
• American Society of Anesthesiologists (ASA) 
• Odds ratio (OR) 
• Confidence interval (CI) 
• Transurethral resection of bladder tumor (TURBT) 
• Urothelial carcinoma (UCC) 
• Disease-specific (DSS) 
• Overall survival (OS) 
